Pfizer Inc

Pfizer CEO Albert Bourla buys phantom‑stock after FDA approves new oncology drug VEPPANU—signaling confidence in the company’s pipeline and potential upside for investors.

Pfizer insiders surge in phantom‑stock buying—boosting confidence in oncology, AI drug development and future value.

Pfizer CEO Albert Bourla’s recent phantom‑stock purchases show insider confidence, hinting at a bullish outlook for Pfizer’s pipeline and long‑term value.

Insider confidence at Pfizer: Senior VP Dennis P. keeps a steady stake while others buy phantom stock, signaling long‑term optimism for the pharma giant.

Pfizer insider confidence: senior execs hold 45K shares and SARs, boosting long‑term growth signals amid market volatility.

Pfizer insider Boulla’s recent phantom‑stock purchase signals confidence in the company’s near‑term earnings and long‑term pipeline, reinforcing its bullish outlook.

Pfizer CEO Albert Bourla buys more phantom stock, signaling confidence in the drugmaker’s upside as shares near a 52‑week high.

Pfizer insiders, including Quincey James, keep buying phantom stock units, signaling long‑term confidence in the company’s oncology and immunology growth.

Pfizer board member Buckley Mortimer’s 1,386 phantom‑stock unit purchase signals strong insider confidence, aligning long‑term goals with shareholder value.

Insider buying at Pfizer signals confidence in its GLP‑1 & oncology pipeline – senior leaders’ RSU purchases and sales suggest long‑term upside.